Journal article
Variants in the APOE Gene Are Associated with Improved Outcome after Anti-VEGF Treatment for Neovascular AMD
Sanjeewa S Wickremasinghe, Jing Xie, Jonathan Lim, Devinder S Chauhan, Luba Robman, Andrea J Richardson, Gregory Hageman, Paul N Baird, Robyn Guymer
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | ASSOC RESEARCH VISION OPHTHALMOLOGY INC | Published : 2011
DOI: 10.1167/iovs.10-6550
Abstract
PURPOSE: Anti-vascular endothelial growth factor (anti-VEGF) drugs have dramatically improved the treatment of neovascular AMD. In pivotal studies, almost 90% of patients maintain vision, with approximately 30% showing significant improvement. Despite these successes, 10% to 15% of patients continue to lose vision, even with treatment. It has been reported that variants in some AMD-associated genes influence treatment outcome. This study showed an association of treatment outcome with variants in the apolipoprotein E (APOE) gene. METHODS: One hundred ninety-two patients receiving anti-VEGF treatment for subfoveal choroidal neovascularization secondary to AMD were enrolled. Information on dem..
View full abstractGrants
Awarded by National Health and Medical Research Council (NHMRC) Centre for Clinical Research Excellence
Awarded by NHMRC
Awarded by National Institutes of Health
Awarded by NATIONAL EYE INSTITUTE
Funding Acknowledgements
Supported by National Health and Medical Research Council (NHMRC) Centre for Clinical Research Excellence Grant 529923; NHMRC Project Grant 590205; NHMRC practitioner fellowship (RG); and National Institutes of Health Grant NIH R24 EY017404 (GH, RG & PB) and a Novartis fellowship (SSW). CERA receives Operational Infrastructure Support from the Victorian Government.